149 related articles for article (PubMed ID: 38190596)
21. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
Purpura CA; Garry EM; Honig N; Case A; Rassen JA
Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
Zheng SY; Dhruva SS; Redberg RF
JAMA; 2017 Aug; 318(7):619-625. PubMed ID: 28810022
[TBL] [Abstract][Full Text] [Related]
23. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
Ronquillo JG; Zuckerman DM
Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
[TBL] [Abstract][Full Text] [Related]
24. Medical Device Approvals Through the Premarket Approval Pathway in Obstetrics and Gynecology From 2000 to 2015: Process and Problems.
Walter JR; Hayman E; Tsai S; Ghobadi CW; Xu S
Obstet Gynecol; 2016 Jun; 127(6):1110-1117. PubMed ID: 27159747
[TBL] [Abstract][Full Text] [Related]
25. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
Mooghali M; Mitchell AP; Skydel JJ; Ross JS; Wallach JD; Ramachandran R
BMJ Med; 2024; 3(1):e000802. PubMed ID: 38596814
[TBL] [Abstract][Full Text] [Related]
26. Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice.
Deyo RA
J Am Board Fam Pract; 2004; 17(2):142-9. PubMed ID: 15082674
[TBL] [Abstract][Full Text] [Related]
27. Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017.
Dubin JR; Simon SD; Norrell K; Perera J; Gowen J; Cil A
JAMA Netw Open; 2021 May; 4(5):e217274. PubMed ID: 33956132
[TBL] [Abstract][Full Text] [Related]
28. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
29. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
[TBL] [Abstract][Full Text] [Related]
30. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
31. Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.
Dhruva SS; Darrow JJ; Kesselheim AS; Redberg RF
J Gen Intern Med; 2022 Dec; 37(16):4176-4182. PubMed ID: 35138547
[TBL] [Abstract][Full Text] [Related]
32. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
33. Oversight overhaul: eliminating the premarket review of medical devices and implementing a provider-centered postmarket surveillance strategy.
Scott B
Food Drug Law J; 2011; 66(3):377-404, ii. PubMed ID: 24505854
[TBL] [Abstract][Full Text] [Related]
34. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program.
Moneer O; Rathi VK; Johnston JL; Ross JS; Dhruva SS
JAMA Cardiol; 2023 Dec; 8(12):1174-1181. PubMed ID: 37878306
[TBL] [Abstract][Full Text] [Related]
35. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.
Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):285-288. PubMed ID: 28093943
[TBL] [Abstract][Full Text] [Related]
36. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
Beakes-Read G; Neisser M; Frey P; Guarducci M
Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
[TBL] [Abstract][Full Text] [Related]
37. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
Sasinowski FJ; Varond AJ
Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
[TBL] [Abstract][Full Text] [Related]
38. Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA.
Hiayev S; Shacham-Shmueli E; Berkovitch M; Weiss I; Ashkenazi S; Vexberg MH; Hershkowitz R; Gorelik E; Mayan H; Steinmetz Y; Yanai NB; Schlissel O; Azem M; Gutgold N; Shulman K; Divinsky M; Yarom N; Vishkautzan A; Ganzel C; Gatt ME; Arcavi L; Marom E; Uziely B; Zevin S; Meirow H; Luxenburg O; Ainbinder D
BMJ Open; 2023 May; 13(5):e067313. PubMed ID: 37142315
[TBL] [Abstract][Full Text] [Related]
39. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
40. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
Eadie A; MacGregor A; Wallach J; Ross J; Herder M
BMJ Evid Based Med; 2023 Jun; 28(3):151-156. PubMed ID: 36944478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
